These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412 [TBL] [Abstract][Full Text] [Related]
25. Galectin-3 as a candidate upstream biomarker for quantifying risks of myocardial ageing. Keng BMH; Gao F; Ewe SH; Tan RS; Teo LLY; Xie BQ; Koh WP; Koh AS ESC Heart Fail; 2019 Oct; 6(5):1068-1076. PubMed ID: 31392851 [TBL] [Abstract][Full Text] [Related]
26. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565 [TBL] [Abstract][Full Text] [Related]
27. Elevated circulating IL-32 presents a poor prognostic outcome in patients with heart failure after myocardial infarction. Xuan W; Huang W; Wang R; Chen C; Chen Y; Wang Y; Tan X Int J Cardiol; 2017 Sep; 243():367-373. PubMed ID: 28747035 [TBL] [Abstract][Full Text] [Related]
28. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888 [TBL] [Abstract][Full Text] [Related]
29. Plasma galectin 3 and heart failure risk in the Physicians' Health Study. Djoussé L; Matsumoto C; Petrone A; Weir NL; Tsai MY; Gaziano JM Eur J Heart Fail; 2014 Mar; 16(3):350-4. PubMed ID: 24464746 [TBL] [Abstract][Full Text] [Related]
30. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Grandin EW; Jarolim P; Murphy SA; Ritterova L; Cannon CP; Braunwald E; Morrow DA Clin Chem; 2012 Jan; 58(1):267-73. PubMed ID: 22110019 [TBL] [Abstract][Full Text] [Related]
31. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. Ghorbani A; Bhambhani V; Christenson RH; Meijers WC; de Boer RA; Levy D; Larson MG; Ho JE J Am Coll Cardiol; 2018 Dec; 72(25):3246-3254. PubMed ID: 30573026 [TBL] [Abstract][Full Text] [Related]
32. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists. Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035 [TBL] [Abstract][Full Text] [Related]
33. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913 [TBL] [Abstract][Full Text] [Related]
34. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. Singsaas EG; Manhenke CA; Dickstein K; Orn S Cardiology; 2016; 134(4):398-405. PubMed ID: 27120522 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of galectin-3 post-infarction impedes progressive fibrosis by regulating inflammatory profibrotic cascades. Wang X; Gaur M; Mounzih K; Rodriguez HJ; Qiu H; Chen M; Yan L; Cooper BA; Narayan S; Derakhshandeh R; Rao P; Han DD; Nabavizadeh P; Springer ML; John CM Cardiovasc Res; 2023 Nov; 119(15):2536-2549. PubMed ID: 37602717 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of cardiac time intervals by tissue Doppler imaging M-mode in patients with acute ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention. Biering-Sørensen T; Mogelvang R; Søgaard P; Pedersen SH; Galatius S; Jørgensen PG; Jensen JS Circ Cardiovasc Imaging; 2013 May; 6(3):457-65. PubMed ID: 23536267 [TBL] [Abstract][Full Text] [Related]
37. Serial galectin-3 and future cardiovascular disease in the general population. van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804 [TBL] [Abstract][Full Text] [Related]
38. Galectin-3 as a Predictor of Long-term Survival After Isolated Coronary Artery Bypass Grafting Surgery. Parker DM; Owens SL; Ramkumar N; Likosky D; DiScipio AW; Malenka DJ; MacKenzie TA; Brown JR Ann Thorac Surg; 2020 Jan; 109(1):132-138. PubMed ID: 31336070 [TBL] [Abstract][Full Text] [Related]
39. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Hashmi S; Al-Salam S Cardiovasc Pathol; 2015; 24(4):213-23. PubMed ID: 25547609 [TBL] [Abstract][Full Text] [Related]
40. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Thune JJ; Signorovitch JE; Kober L; McMurray JJ; Swedberg K; Rouleau J; Maggioni A; Velazquez E; Califf R; Pfeffer MA; Solomon SD Eur J Heart Fail; 2011 Feb; 13(2):148-53. PubMed ID: 21037250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]